{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T22:53:29Z","timestamp":1776207209234,"version":"3.50.1"},"reference-count":23,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jiac-j.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Infection and Chemotherapy"],"published-print":{"date-parts":[[2015,9]]},"DOI":"10.1016\/j.jiac.2015.05.011","type":"journal-article","created":{"date-parts":[[2015,6,13]],"date-time":"2015-06-13T03:28:01Z","timestamp":1434166081000},"page":"663-667","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["Pharmacokinetics of posaconazole prophylaxis of patients with acute myeloid leukemia"],"prefix":"10.1016","volume":"21","author":[{"given":"Gloria","family":"Mattiuzzi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Musa","family":"Yilmaz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hagop","family":"Kantarjian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gautam","family":"Borthakur","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marina","family":"Konopleva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elias","family":"Jabbour","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yolanda","family":"Brown","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sherry","family":"Pierce","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jorge","family":"Cortes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jiac.2015.05.011_bib1","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1128\/AAC.50.1.143-147.2006","article-title":"Open-label, randomized comparison of itraconazole versus caspofungin for prophylaxis in patients with hematologic malignancies","volume":"50","author":"Mattiuzzi","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jiac.2015.05.011_bib2","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1002\/cncr.11094","article-title":"Liposomal amphotericin b versus the combination of fluconazole and itraconazole as prophylaxis for invasive fungal infections during induction chemotherapy for patients with acute myelogenous leukemia and myelodysplastic syndrome","volume":"97","author":"Mattiuzzi","year":"2003","journal-title":"Cancer"},{"key":"10.1016\/j.jiac.2015.05.011_bib3","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1002\/cncr.11936","article-title":"Amphotericin b lipid complex as prophylaxis of invasive fungal infections in patients with acute myelogenous leukemia and myelodysplastic syndrome undergoing induction chemotherapy","volume":"100","author":"Mattiuzzi","year":"2004","journal-title":"Cancer"},{"key":"10.1016\/j.jiac.2015.05.011_bib4","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1002\/cncr.11930","article-title":"Intravenous itraconazole for prophylaxis of systemic fungal infections in patients with acute myelogenous leukemia and high-risk myelodysplastic syndrome undergoing induction chemotherapy","volume":"100","author":"Mattiuzzi","year":"2004","journal-title":"Cancer"},{"key":"10.1016\/j.jiac.2015.05.011_bib5","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1056\/NEJMoa061094","article-title":"Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia","volume":"356","author":"Cornely","year":"2007","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jiac.2015.05.011_bib6","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1056\/NEJMoa061098","article-title":"Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease","volume":"356","author":"Ullmann","year":"2007","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jiac.2015.05.011_bib7","doi-asserted-by":"crossref","first-page":"3637","DOI":"10.1128\/AAC.00662-08","article-title":"Activities of antifungal agents against yeasts and filamentous fungi: assessment according to the methodology of the european committee on antimicrobial susceptibility testing","volume":"52","author":"Lass-Florl","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jiac.2015.05.011_bib8","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1046\/j.1365-2125.2003.01977.x","article-title":"Effect of food on the relative bioavailability of two oral formulations of posaconazole in healthy adults","volume":"57","author":"Courtney","year":"2004","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.jiac.2015.05.011_bib9","doi-asserted-by":"crossref","first-page":"725","DOI":"10.2165\/11592630-000000000-00000","article-title":"Effect of pH and comedication on gastrointestinal absorption of posaconazole: monitoring of intraluminal and plasma drug concentrations","volume":"50","author":"Walravens","year":"2011","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.jiac.2015.05.011_bib10","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1592\/phco.27.12.1627","article-title":"Pharmacokinetics of oral posaconazole in allogeneic hematopoietic stem cell transplant recipients with graft-versus-host disease","volume":"27","author":"Krishna","year":"2007","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.jiac.2015.05.011_bib11","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1128\/AAC.01034-08","article-title":"Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers","volume":"53","author":"Krishna","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jiac.2015.05.011_bib12","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1177\/1078155208094123","article-title":"Breakthrough invasive fungal infection in an immunocompromised host while on posaconazole prophylaxis: an omission in patient counseling and follow-up","volume":"14","author":"Kishel","year":"2008","journal-title":"J\u00a0Oncol Pharm Pract"},{"key":"10.1016\/j.jiac.2015.05.011_bib13","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1038\/bmt.2008.199","article-title":"Breakthrough rhizopus infection on posaconazole prophylaxis following allogeneic stem cell transplantation","volume":"42","author":"Schlemmer","year":"2008","journal-title":"Bone Marrow Transpl"},{"key":"10.1016\/j.jiac.2015.05.011_bib14","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/j.ijantimicag.2008.04.014","article-title":"Fatal aspergillus fumigatus and candida glabrata infections with posaconazole prophylaxis after stem cell transplantation","volume":"32","author":"Ustun","year":"2008","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.jiac.2015.05.011_bib15","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1086\/323335","article-title":"Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus","volume":"34","author":"Ascioglu","year":"2002","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jiac.2015.05.011_bib16","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1128\/AAC.01558-13","article-title":"A\u00a0reference laboratory experience of clinically achievable voriconazole, posaconazole, and itraconazole concentrations within the bloodstream and cerebral spinal fluid","volume":"58","author":"Wiederhold","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jiac.2015.05.011_bib17","doi-asserted-by":"crossref","first-page":"2223","DOI":"10.1128\/AAC.00240-09","article-title":"2nd. Posaconazole therapeutic drug monitoring: a reference laboratory experience","volume":"53","author":"Thompson","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jiac.2015.05.011_bib18","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.diagmicrobio.2012.10.001","article-title":"Epidemiology, outcomes, and risk factors of invasive fungal infections in adult patients with acute myelogenous leukemia after induction chemotherapy","volume":"75","author":"Neofytos","year":"2013","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.jiac.2015.05.011_bib19","doi-asserted-by":"crossref","first-page":"20","DOI":"10.3109\/10428190903242602","article-title":"Primary antifungal prophylaxis in acute myeloblastic leukemia and myelodysplastic syndrome\u2013still an open question?","volume":"51","author":"Ruping","year":"2010","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.jiac.2015.05.011_bib20","doi-asserted-by":"crossref","first-page":"211","DOI":"10.2165\/00003088-200544020-00006","article-title":"Oral bioavailability of posaconazole in fasted healthy subjects: comparison between three regimens and basis for clinical dosage recommendations","volume":"44","author":"Ezzet","year":"2005","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.jiac.2015.05.011_bib21","doi-asserted-by":"crossref","first-page":"2788","DOI":"10.1128\/AAC.47.9.2788-2795.2003","article-title":"Pharmacokinetics, safety, and tolerability of oral posaconazole administered in single and multiple doses in healthy adults","volume":"47","author":"Courtney","year":"2003","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jiac.2015.05.011_bib22","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1128\/AAC.00157-06","article-title":"Pharmacokinetics and safety of oral posaconazole in neutropenic stem cell transplant recipients","volume":"50","author":"Gubbins","year":"2006","journal-title":"Antimicrob Agents Ch"},{"key":"10.1016\/j.jiac.2015.05.011_bib23","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1592\/phco.28.10.1223","article-title":"Pharmacokinetics of oral posaconazole in neutropenic patients receiving chemotherapy for acute myelogenous leukemia or myelodysplastic syndrome","volume":"28","author":"Krishna","year":"2008","journal-title":"Pharmacotherapy"}],"container-title":["Journal of Infection and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1341321X15001361?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1341321X15001361?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T18:53:55Z","timestamp":1761159235000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1341321X15001361"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,9]]},"references-count":23,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2015,9]]}},"alternative-id":["S1341321X15001361"],"URL":"https:\/\/doi.org\/10.1016\/j.jiac.2015.05.011","relation":{},"ISSN":["1341-321X"],"issn-type":[{"value":"1341-321X","type":"print"}],"subject":[],"published":{"date-parts":[[2015,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pharmacokinetics of posaconazole prophylaxis of patients with acute myeloid leukemia","name":"articletitle","label":"Article Title"},{"value":"Journal of Infection and Chemotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jiac.2015.05.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}